会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Compound preparation for the treatment of hypogonadal men and men with
hypophyseal diseases
    • 复方制剂治疗性腺功能减退的男性和男性患有垂体病
    • US5855905A
    • 1999-01-05
    • US841719
    • 1997-04-30
    • Michael OettelSiegfried GolbsMichael DittgenCarsten TimpeThomas GraserDoris Hubler
    • Michael OettelSiegfried GolbsMichael DittgenCarsten TimpeThomas GraserDoris Hubler
    • A61K31/565
    • A61K31/565
    • A compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases. This invention relates to compound preparations containing biogenous or synthetic androgens and biogenous or synthetic estrogens that are used for the treatment of imbalances of the testosterone metabolism in old age, of hypogonadal men, and of men with hypophyseal diseases. These compound preparations are present in various galenic formulations such as ointments, gels, sprays, TTS systems, tablets, lozenges, capsules, and suppositories. These preparations are used to treat the fluctuations of the testosterone metabolism occurring in old age and with certain diseases such as hypophyseal diseases (adenoma), hypogonadism and/or metabolic syndrome, to maintain the balance between androgens and estrogens found in young and healthy men in ill and/or elderly men as well. The preparations for treating these imbalances are suitable for oral, parenteral, percutaneous, sublingual or rectal administration depending on their galenic form. Thus, unphysiological changes in steroid-converting enzymes such as aromatases and reductases are avoided, which considerably improves the outcome of the therapy.
    • 用于治疗性腺功能减退的男性和男性的复方制剂。 本发明涉及包含生物或合成雄激素和生物或合成雌激素的化合物制剂,其用于治疗老年睾酮代谢失调,性腺机能不良男性和具有垂体浸润性疾病的男性的不平衡。 这些复合制剂存在于各种盖仑制剂如软膏,凝胶剂,喷雾剂,TTS系统,片剂,锭剂,胶囊和栓剂中。 这些制剂用于治疗老年发生的睾酮代谢的波动,以及诸如垂体疾病(腺瘤),性腺机能减退和/或代谢综合征等某些疾病,以维持年轻和健康男性发现的雄激素和雌激素之间的平衡 生病和/或老年男子。 用于治疗这些不平衡的制剂适用于口服,肠胃外,经皮,舌下或直肠给药,取决于其盖仑形式。 因此,避免类固醇转化酶如芳香酶和还原酶的非生理变化,这显着改善了治疗的结果。
    • 2. 发明授权
    • Hormonal agent for skin treatment
    • 皮肤治疗激素剂
    • US06225299B1
    • 2001-05-01
    • US09219660
    • 1998-12-23
    • Siegfried GolbsMichael OettelMichael DittgenThomas GraserChristoph Luderschmidt
    • Siegfried GolbsMichael OettelMichael DittgenThomas GraserChristoph Luderschmidt
    • A61K3156
    • A61K31/56A61K8/63A61Q7/00Y10S514/859Y10S514/864
    • The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin. The pharmaceutical preparation including the dienogest and conventional dermatologically acceptable carrier and auxiliary substances in the described galenic formulation advantageously provides a drastic reduction in androstandiol glucuronide and moderate androgen receptor blockage without passing through the skin barrier so that systemic effects including side reactions are substantially prevented.
    • 药物组合物,特别是用于治疗皮脂溢,皮肤寻常痤疮和阴道调理性脱发的皮肤,含有激素剂,包括睾酮,依那诺或二烯酸和雌激素的组合作为活性成分。 用于治疗这种类型皮肤病症的方法包括局部应用组合物,其包括引起明显的抑制作用的替奈格明,葡萄糖醛酸葡萄糖醛酸葡聚糖和葡萄糖醛酸葡聚糖的剧烈降低以及雄激素受体位点的适度竞争性阻断。 描述了限制和/或防止活性成分渗透皮肤的Galenic制剂。 在所述盖仑制剂中包含地那烯酸和常规皮肤病学可接受的载体和辅助物质的药物制剂有利地提供了葡萄糖醛酸葡萄糖醛酸葡萄糖苷和中和雄激素受体阻断物的急剧降低,而不会通过皮肤屏障,从而基本上防止包括副反应的全身效应。
    • 3. 发明授权
    • Hormonal agent for skin treatment
    • 皮肤治疗激素剂
    • US5910493A
    • 1999-06-08
    • US714463
    • 1996-09-16
    • Siegfried GolbsMichael OettelMichael DittgenThomas GraserChristoph Luderschmidt
    • Siegfried GolbsMichael OettelMichael DittgenThomas GraserChristoph Luderschmidt
    • A61K8/63A61Q5/00A61Q7/00A61Q19/00A61K31/56
    • A61K31/567A61K8/63A61Q19/00A61Q5/00A61Q7/00Y10S514/859Y10S514/864
    • The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin. The pharmaceutical preparation including the dienogest and conventional dermatologically acceptable carrier and auxiliary substances in the described galenic formulation advantageously provides a drastic reduction in androstandiol glucuronide and moderate androgen receptor blockage without passing through the skin barrier so that systemic effects including side reactions are substantially prevented.
    • 药物组合物,特别是用于治疗皮脂溢,皮肤寻常痤疮和阴道调理性脱发的皮肤,含有激素剂,包括睾酮,依那诺或二烯酸和雌激素的组合作为活性成分。 用于治疗这种类型皮肤病症的方法包括局部应用组合物,其包括引起明显的抑制作用的替奈格明,葡萄糖醛酸葡萄糖醛酸葡聚糖和葡萄糖醛酸葡聚糖的剧烈降低以及雄激素受体位点的适度竞争性阻断。 描述了限制和/或防止活性成分渗透皮肤的Galenic制剂。 在所述盖仑制剂中包含地那烯酸和常规皮肤病学可接受的载体和辅助物质的药物制剂有利地提供了葡萄糖醛酸葡萄糖醛酸葡萄糖苷和中和雄激素受体阻断物的急剧降低,而不会通过皮肤屏障,从而基本上防止包括副反应的全身效应。